drugset / Trial / NCT02970929

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

NCT02970929

NaSingle-groupOpen-labelTreatment

Summary

An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia

Timeline

Start
2017-01-31
Primary completion
2019-01-29
Completion
2019-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulotaront Small molecule 25 mg
Subject Ulotaront Small molecule 50 mg
Subject Ulotaront Small molecule 75 mg

Indications